Results 141 to 150 of about 3,535 (191)
A Retrospective Database Analysis of Anticholinergic Burden Among Older Patients With and Without Overactive Bladder in South Korea. [PDF]
Int Neurourol JLee KS +7 more
europepmc +1 more source
Mirabegron in the treatment of overactive bladder
Expert Opinion on Pharmacotherapy, 2014 Mirabegron is a selective β3-adrenergic receptor agonist recently developed for the treatment of patients with overactive bladder (OAB), which offers an alternative pharmacological option to the well-established treatment with antimuscarinics (AMs).This review offers an explanation of the mechanism of action, of the pharmacokinetics and ...
Leone Roberti Maggiore U +9 more
openaire +7 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Expert Opinion on Drug Safety, 2010
Mirabegron is being developed as a new treatment for the management of overactive bladder (OAB). It is an orally active drug that works by activating the β(3)-adrenoceptor with a better safety profile than antimuscarinic drugs. However, long-term adverse effects are not yet completely investigated.The following article reviews the pharmacology and ...
Pradeep, Tyagi +2 more
openaire +2 more sources
Mirabegron is being developed as a new treatment for the management of overactive bladder (OAB). It is an orally active drug that works by activating the β(3)-adrenoceptor with a better safety profile than antimuscarinic drugs. However, long-term adverse effects are not yet completely investigated.The following article reviews the pharmacology and ...
Pradeep, Tyagi +2 more
openaire +2 more sources
Mirabegron: Pediatric First Approval
Pediatric Drugs, 2021Mirabegron (MYRBETRIQ®), a beta-3 adrenergic agonist developed by Astellas Pharma Inc., is well established as a treatment for overactive bladder in adults and is available as extended-release (ER) tablets administered once daily. More recently, mirabegron has been investigated in pediatric patients with neurogenic detrusor overactivity (NDO) and ...
openaire +2 more sources
▼Mirabegron for overactive bladder syndrome
Drug and Therapeutics Bulletin, 2013Urinary incontinence, the involuntary leakage of urine, can result from abnormalities of the urinary tract or may be caused by other conditions and is sub-divided into a number of classifications including stress incontinence and urge urinary incontinence.1 Urge urinary incontinence (UUI) is involuntary urine leakage accompanied by urgency of ...
openaire +2 more sources
Mirabegron for the treatment of overactive bladder
Drugs of Today, 2012Overactive bladder (OAB) syndrome is defined as urinary urgency, usually accompanied by frequency and nocturia, with or without urge urinary incontinence, in the absence of urinary tract infection or other obvious pathology. Mirabegron (YM-178, Betanis®) is a novel, once-daily, orally active, first-in-class selective β(3)-adrenoceptor agonist that ...
openaire +2 more sources